Next Article in Journal
Covalent Organic Frameworks: A Promising Materials Platform for Photocatalytic CO2 Reductions
Previous Article in Journal
Nutrient and Sensory Metabolites Profiling of Averrhoa Carambola L. (Starfruit) in the Context of Its Origin and Ripening Stage by GC/MS and Chemometric Analysis

Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming

Division of Biomedical Sciences, School of Medicine, University of California Riverside, Riverside, CA 92521, USA
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
Author to whom correspondence should be addressed.
Current address: Takeda California, Inc., San Diego, CA 92121, USA.
Molecules 2020, 25(10), 2424;
Received: 28 April 2020 / Revised: 18 May 2020 / Accepted: 20 May 2020 / Published: 22 May 2020
Processing of certain viral proteins and bacterial toxins by host serine proteases is a frequent and critical step in virulence. The coronavirus spike glycoprotein contains three (S1, S2, and S2′) cleavage sites that are processed by human host proteases. The exact nature of these cleavage sites, and their respective processing proteases, can determine whether the virus can cross species and the level of pathogenicity. Recent comparisons of the genomes of the highly pathogenic SARS-CoV2 and MERS-CoV, with less pathogenic strains (e.g., Bat-RaTG13, the bat homologue of SARS-CoV2) identified possible mutations in the receptor binding domain and in the S1 and S2′ cleavage sites of their spike glycoprotein. However, there remains some confusion on the relative roles of the possible serine proteases involved for priming. Using anthrax toxin as a model system, we show that in vivo inhibition of priming by pan-active serine protease inhibitors can be effective at suppressing toxicity. Hence, our studies should encourage further efforts in developing either pan-serine protease inhibitors or inhibitor cocktails to target SARS-CoV2 and potentially ward off future pandemics that could develop because of additional mutations in the S-protein priming sequence in coronaviruses. View Full-Text
Keywords: COVID19; SARS-COV2; Anthrax toxin; protecting antigen; furin; TMPRSS2 COVID19; SARS-COV2; Anthrax toxin; protecting antigen; furin; TMPRSS2
Show Figures

Graphical abstract

MDPI and ACS Style

Barile, E.; Baggio, C.; Gambini, L.; Shiryaev, S.A.; Strongin, A.Y.; Pellecchia, M. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming. Molecules 2020, 25, 2424.

AMA Style

Barile E, Baggio C, Gambini L, Shiryaev SA, Strongin AY, Pellecchia M. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming. Molecules. 2020; 25(10):2424.

Chicago/Turabian Style

Barile, Elisa, Carlo Baggio, Luca Gambini, Sergey A. Shiryaev, Alex Y. Strongin, and Maurizio Pellecchia. 2020. "Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming" Molecules 25, no. 10: 2424.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop